Search results for " peptide"

showing 10 items of 2395 documents

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

B-type natriuretic peptides and thyroid disease

2010

natriuretic peptidethyroid
researchProduct

Clinical utilization of natriuretic peptide determination in acute congestive heart failure

2010

natriuretic peptides heart failure
researchProduct

Enkephalin-containing interneurons are specialized to innervate other interneurons in the hippocampal CA1 region of the rat and guinea-pig

1998

Enkephalins are known to have a profound effect on hippocampal inhibition, but the possible endogenous source of these neuropeptides, and their relationship to inhibitory interneurons is still to be identified. In the present study we analysed the morphological characteristics of met-enkephalin-immunoreactive cells in the CA1 region of the rat and guinea-pig hippocampus, their coexistence with other neuronal markers and their target selectivity at the light and electron microscopic levels.  Several interneurons in all subfields of the hippocampus were found to be immunoreactive for met-enkephalin. In the guinea-pig, fibres arising from immunoreactive interneurons were seen to form a plexus …

nervous systemEnkephalinPostsynaptic potentialmusculoskeletal neural and ocular physiologyGeneral NeuroscienceVasoactive intestinal peptideHippocampusGABAergicHippocampal formationCalretininBiologyInhibitory postsynaptic potentialNeuroscienceEuropean Journal of Neuroscience
researchProduct

Il controllo nitrossidergico e peptidergico della secrezione salivare nella parotide di alcuni mammiferi

2006

nitrossidergico e peptidergico
researchProduct

Identification and quantification of phosphatidylcholines containing very long chain polyunsaturated fatty acid (VLC-PUFA) in bovine and human retina…

2010

The retina is one of the vertebrate tissues with the highest content in polyunsaturated fatty acids (PUFA). A large proportion of the retinal glycerophospholipids, especially those found in photoreceptor membranes, are dipolyunsaturated molecular species. Among them, dipolyunsaturated phosphatidylcholine molecular species are known to contain very long chain polyunsaturated fatty acids (VLC-PUFA) from the n-3 and n-6 series and having 24 to 36 carbon atoms (C24 to C36) and four to six double bonds. Recent interest in the role of VLC-PUFA arose from the findings that a protein named ELOngation of Very Long chain fatty acids 4 (ELOVL4) is involved in their biosynthesis and that mutations in E…

normal phase chromatographyhplc chromatographyretinacoupled methodcomplex lipidvertebrataadsorption chromatography[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologytandem mass spectrometryqualitative analysisanimalhumanungulataphosphatidylcholinephospholipid[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologylong chainquantitative analysisbovinepolyunsaturated fatty acideyeeye diseasesanalysis methodartiodactylalipids (amino acids peptides and proteins)mammaliaelectrospray[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Additional file 1 of Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): …

2021

Additional file 1: Table 1. Patients’ genotypes. All mutations were classified according to ACMG guidelines (Chora JR, Medeiros AM, Alves AC, Bourbon M. Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. Genet Med. 2018;20(6):591-598). For 3 Homozygous LDLR and 1 LDLRAP1 causing mutations were not available and the diagnosis was only on clinical base. *Double Heterozygote patient for mutations in both LDLR (c.373C>T) and PCSK9 (c.60_ 65dupGCTGCT) genes.

nutritional and metabolic diseaseslipids (amino acids peptides and proteins)
researchProduct

MOESM1 of Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

2019

Additional file 1: Appendix 1. Assessment of risk of bias in the included studies using Cochrane criteria for RCTs. Appendix 2. Assessment of risk of bias in the included studies using Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies. Figure S1. Association of statin versus non-statin use with all-cause mortality in heart failure only in cohort studies. Figure. S2. Association of statin versus non-statin use with CV mortality in heart failure only in cohort studies. Figure S3. Association of statin versus non-statin use hospitalization in heart failure only in cohort studies. Figure S4. Association of statin versus non-statin use with all-cause mortality by type of heart f…

nutritional and metabolic diseaseslipids (amino acids peptides and proteins)cardiovascular diseases
researchProduct

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

2013

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in t…

obesitymedicine.medical_specialtyVery low-density lipoproteinLipoproteinslipid-lowering drugsanti-obesity drugslcsh:TX341-641030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyOverweight03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinInternal medicineHumansMedicineRisk factorDyslipidemiasMetabolic Syndromeobesity treatmentNutrition and Dieteticssmall dense low density lipoproteinbusiness.industryCholesterollipoproteinmedicine.disease3. Good healthEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinlipids (amino acids peptides and proteins)Metabolic syndromemedicine.symptombusinesslcsh:Nutrition. Foods and food supplyanti-obesity drugFood ScienceLipoproteinNutrients
researchProduct

Effet anti-obésité des CLA : mythe ou réalité ?

2005

Conjugated linoleic acids (CLA) are positional and geometric isomers of linoleic acid. Inclusion of CLA in the diet provokes a rapid and marked decrease in body weight gain and adiposity in mice leading to a lipoatrophic syndrome. However, CLA supplementation raised fasting blood glucose and insulin concentrations and was associated with severe insulin resistance and liversteatosis. Conflicting results have been reported with regard to reduction of fat mass in humans. We have reviewed the publish literature regarding the effect of CLA on body composition in humans and animal models. These studies indicate that t10-c12 was the isomer that reduced adipose fat storage, however it also increase…

obesitymedicine.medical_specialtymedicine.medical_treatmentConjugated linoleic acidAdipose tissuelcsh:TP670-699BiologyadipocyteBiochemistryliver steatosischemistry.chemical_compoundlipoatrophic diabetesInsulin resistanceInternal medicineAdipocytemedicinelipogenesisUnsaturated fatty acidLipoatrophic diabetesintegumentary systemInsulinFatty liverfood and beveragesmedicine.diseaseEndocrinologychemistrylipids (amino acids peptides and proteins)lcsh:Oils fats and waxesFood ScienceOléagineux, Corps gras, Lipides
researchProduct